Safety and tolerability of rapid dose-titration of subcutaneous (SC) treprostinil in pulmonary arterial hypertension (PAH)

Grünig, Ekkehard; Egenlauf, Benjamin; Lange, Tobias; Krüger, Ulrich; Grover, R.; Pernow, Michelle; Traube, Andrew; Viethen, Thomas; Rosenkranz, Stephan

doi:10.1183/13993003.congress-2015.pa2114

Search citation statements

Order By: Relevance

Paper Sections

Select...

+ + Iii-iv Intravenous Continuous1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…¶ ¶ : active selexipag metabolite. varies depending on the drug (table 2 [29]). Selexipag is an example of a therapy that is up-titrated to the individual patient's highest tolerated dose, up to a maximum of 1600 µg twice daily [12,13].…”

Section: + + Iii-iv Intravenous Continuousmentioning

confidence: 99%

Practical considerations for therapies targeting the prostacyclin pathway

Farber

Gin-Sing

2016

Eur Respir Rev

View full text Add to dashboard Cite

Therapies that target the prostacyclin pathway play a key role in the treatment of both early- and late-stage pulmonary arterial hypertension, and provide significant clinical benefits for patients. A number of agents have been approved, which are administered via intravenous, subcutaneous, inhaled or oral routes. The use of these therapies is associated with practical challenges, relating to the need for up-titration and their routes of administration. We discuss here a number of measures that can be taken to support patients and healthcare professionals in order to address the complexities of using these therapies and to encourage compliance. Providing patients with timely information and education, together with practical advice on managing their medication and associated equipment, assists patients with day-to-day management of therapy. Referral to patient associations and support groups can be of further benefit. With an effective management plan and an experienced multidisciplinary team, the use of therapies that target the prostacyclin pathway can be optimised.

show abstract

Section: + + Iii-iv Intravenous Continuousmentioning

confidence: 99%